Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

TY - JOUR

T1 - Personalised reimbursement

T2 - a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

AU - van Waalwijk van Doorn-Khosrovani, S B

AU - Pisters-van Roy, A

AU - van Saase, L

AU - van der Graaff, M

AU - Gijzen, J

AU - Sleijfer, S

AU - Hoes, L R

AU - van Berge Henegouwen, J M

AU - van der Wijngaart, H

AU - van der Velden, D L

AU - van Werkhoven, E

AU - Retel, V P

AU - van Harten, W H

AU - Huitema, A D R

AU - Timmers, L

AU - Gelderblom, H

AU - Verheul, H M W

AU - Voest, E E

N1 - Funding Information: The DRUP trial is supported by the Barcode for Life Foundation (grant number not applicable); the Dutch Cancer Society (grant number 10014); and all participating pharmaceutical companies (grant numbers not applicable): Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Novartis, Merck Sharp & Dohme, Pfizer and Roche. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2019/5/1

Y1 - 2019/5/1

UR - https://www.scopus.com/pages/publications/85067377129

U2 - 10.1093/annonc/mdz119

DO - 10.1093/annonc/mdz119

M3 - Editorial

C2 - 31038154

SN - 0923-7534

VL - 30

SP - 663

EP - 665

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 5

M1 - mdz119

ER -